Shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) have been assigned a consensus rating of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $2.83.
A number of analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Tuesday, September 25th. JPMorgan Chase & Co. cut Infinity Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research note on Monday, November 12th. Wells Fargo & Co cut Infinity Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, November 12th. UBS Group reissued a “reduce” rating on shares of Infinity Pharmaceuticals in a research report on Monday. Finally, B. Riley initiated coverage on Infinity Pharmaceuticals in a research report on Friday, January 4th. They set a “buy” rating and a $3.00 price objective for the company.
Infinity Pharmaceuticals stock traded up $0.02 during midday trading on Friday, hitting $1.31. 213,300 shares of the stock were exchanged, compared to its average volume of 220,250. Infinity Pharmaceuticals has a fifty-two week low of $1.00 and a fifty-two week high of $2.92. The stock has a market cap of $73.36 million, a P/E ratio of -1.58 and a beta of 2.29.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings results on Monday, November 5th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.37. The firm had revenue of $22.00 million for the quarter. Research analysts anticipate that Infinity Pharmaceuticals will post -0.23 earnings per share for the current fiscal year.
In related news, major shareholder Value Fund L. P. Biotechnology bought 1,469,826 shares of the company’s stock in a transaction that occurred on Wednesday, November 21st. The stock was purchased at an average price of $1.37 per share, for a total transaction of $2,013,661.62. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Bvf Partners L. P/Il bought 91,474 shares of the company’s stock in a transaction that occurred on Thursday, November 15th. The stock was bought at an average price of $1.35 per share, with a total value of $123,489.90. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 3,905,634 shares of company stock valued at $5,300,055. Company insiders own 11.45% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. Opaleye Management Inc. acquired a new stake in shares of Infinity Pharmaceuticals in the third quarter valued at $745,000. EcoR1 Capital LLC grew its stake in shares of Infinity Pharmaceuticals by 12.2% in the third quarter. EcoR1 Capital LLC now owns 462,068 shares of the biotechnology company’s stock valued at $1,252,000 after buying an additional 50,068 shares in the last quarter. Renaissance Technologies LLC grew its position in Infinity Pharmaceuticals by 35.7% in the 3rd quarter. Renaissance Technologies LLC now owns 736,700 shares of the biotechnology company’s stock valued at $1,996,000 after acquiring an additional 194,000 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Infinity Pharmaceuticals by 14.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,065,874 shares of the biotechnology company’s stock valued at $2,889,000 after acquiring an additional 133,504 shares in the last quarter. Finally, Fosun International Ltd acquired a new position in Infinity Pharmaceuticals in the 3rd quarter valued at about $879,000. Hedge funds and other institutional investors own 52.16% of the company’s stock.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Recommended Story: How to Invest in Growth Stocks
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.